JP2022166140A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022166140A5 JP2022166140A5 JP2022127059A JP2022127059A JP2022166140A5 JP 2022166140 A5 JP2022166140 A5 JP 2022166140A5 JP 2022127059 A JP2022127059 A JP 2022127059A JP 2022127059 A JP2022127059 A JP 2022127059A JP 2022166140 A5 JP2022166140 A5 JP 2022166140A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- cancer
- domain
- acid substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 235000001014 amino acid Nutrition 0.000 claims 12
- 238000006467 substitution reaction Methods 0.000 claims 10
- 230000008685 targeting Effects 0.000 claims 9
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 108010079723 Shiga Toxin Proteins 0.000 claims 4
- 239000012636 effector Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 241000251468 Actinopterygii Species 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 102000008102 Ankyrins Human genes 0.000 claims 1
- 108010049777 Ankyrins Proteins 0.000 claims 1
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000002086 C-type lectin-like Human genes 0.000 claims 1
- 108050009406 C-type lectin-like Proteins 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 102100037362 Fibronectin Human genes 0.000 claims 1
- 102000002090 Fibronectin type III Human genes 0.000 claims 1
- 108050009401 Fibronectin type III Proteins 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- -1 Kunitz domain Proteins 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- 102000000853 LDL receptors Human genes 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- 102000019298 Lipocalin Human genes 0.000 claims 1
- 108050006654 Lipocalin Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 102000014400 SH2 domains Human genes 0.000 claims 1
- 108050003452 SH2 domains Proteins 0.000 claims 1
- 102100029198 SLAM family member 7 Human genes 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 101000844753 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) DNA-binding protein 7d Proteins 0.000 claims 1
- 102100038126 Tenascin Human genes 0.000 claims 1
- 108010008125 Tenascin Proteins 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 102000044159 Ubiquitin Human genes 0.000 claims 1
- 108090000848 Ubiquitin Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000003115 germ cell cancer Diseases 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000029255 peripheral nervous system cancer Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000003437 pleural cancer Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 102100039371 ER lumen protein-retaining receptor 1 Human genes 0.000 description 1
- 101000812437 Homo sapiens ER lumen protein-retaining receptor 1 Proteins 0.000 description 1
- 108010030685 KDEL receptor Proteins 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461932000P | 2014-01-27 | 2014-01-27 | |
| US61/932,000 | 2014-01-27 | ||
| US201462049325P | 2014-09-11 | 2014-09-11 | |
| US62/049,325 | 2014-09-11 | ||
| JP2020002993A JP2020073569A (ja) | 2014-01-27 | 2020-01-10 | 哺乳動物への応用のための脱免疫化された志賀毒素ａサブユニットエフェクターポリペプチド |
| JP2021102325A JP7126729B2 (ja) | 2014-01-27 | 2021-06-21 | 哺乳動物への応用のための脱免疫化された志賀毒素ａサブユニットエフェクターポリペプチド |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021102325A Division JP7126729B2 (ja) | 2014-01-27 | 2021-06-21 | 哺乳動物への応用のための脱免疫化された志賀毒素ａサブユニットエフェクターポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022166140A JP2022166140A (ja) | 2022-11-01 |
| JP2022166140A5 true JP2022166140A5 (enExample) | 2022-11-09 |
| JP7402556B2 JP7402556B2 (ja) | 2023-12-21 |
Family
ID=52469328
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016546476A Active JP6655017B2 (ja) | 2014-01-27 | 2015-01-26 | Ｍｈｃクラスｉエピトープ送達ポリペプチド |
| JP2016546493A Active JP6646584B2 (ja) | 2014-01-27 | 2015-01-26 | 哺乳動物への応用のための脱免疫化された志賀毒素ａサブユニットエフェクターポリペプチド |
| JP2020002993A Pending JP2020073569A (ja) | 2014-01-27 | 2020-01-10 | 哺乳動物への応用のための脱免疫化された志賀毒素ａサブユニットエフェクターポリペプチド |
| JP2020014954A Pending JP2020079267A (ja) | 2014-01-27 | 2020-01-31 | Ｍｈｃクラスｉエピトープ送達ポリペプチド |
| JP2021092504A Active JP7229570B2 (ja) | 2014-01-27 | 2021-06-01 | Ｍｈｃクラスｉエピトープ送達ポリペプチド |
| JP2021102325A Active JP7126729B2 (ja) | 2014-01-27 | 2021-06-21 | 哺乳動物への応用のための脱免疫化された志賀毒素ａサブユニットエフェクターポリペプチド |
| JP2022127059A Active JP7402556B2 (ja) | 2014-01-27 | 2022-08-09 | 哺乳動物への応用のための脱免疫化された志賀毒素ａサブユニットエフェクターポリペプチド |
| JP2023016832A Active JP7442879B2 (ja) | 2014-01-27 | 2023-02-07 | Ｍｈｃクラスｉエピトープ送達ポリペプチド |
Family Applications Before (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016546476A Active JP6655017B2 (ja) | 2014-01-27 | 2015-01-26 | Ｍｈｃクラスｉエピトープ送達ポリペプチド |
| JP2016546493A Active JP6646584B2 (ja) | 2014-01-27 | 2015-01-26 | 哺乳動物への応用のための脱免疫化された志賀毒素ａサブユニットエフェクターポリペプチド |
| JP2020002993A Pending JP2020073569A (ja) | 2014-01-27 | 2020-01-10 | 哺乳動物への応用のための脱免疫化された志賀毒素ａサブユニットエフェクターポリペプチド |
| JP2020014954A Pending JP2020079267A (ja) | 2014-01-27 | 2020-01-31 | Ｍｈｃクラスｉエピトープ送達ポリペプチド |
| JP2021092504A Active JP7229570B2 (ja) | 2014-01-27 | 2021-06-01 | Ｍｈｃクラスｉエピトープ送達ポリペプチド |
| JP2021102325A Active JP7126729B2 (ja) | 2014-01-27 | 2021-06-21 | 哺乳動物への応用のための脱免疫化された志賀毒素ａサブユニットエフェクターポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023016832A Active JP7442879B2 (ja) | 2014-01-27 | 2023-02-07 | Ｍｈｃクラスｉエピトープ送達ポリペプチド |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US20160347798A1 (enExample) |
| EP (4) | EP3099705B1 (enExample) |
| JP (8) | JP6655017B2 (enExample) |
| KR (6) | KR102500408B1 (enExample) |
| CN (4) | CN112851769A (enExample) |
| AU (8) | AU2015209063C1 (enExample) |
| CA (1) | CA2937407A1 (enExample) |
| ES (2) | ES2749862T3 (enExample) |
| IL (8) | IL302552B2 (enExample) |
| MX (4) | MX382229B (enExample) |
| WO (2) | WO2015113007A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| CA2848656C (en) | 2010-09-15 | 2017-10-10 | Randall J. Mrsny | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
| EP2639299A1 (en) | 2012-03-16 | 2013-09-18 | Invectys | Universal cancer peptides derived from telomerase |
| CN105051067B (zh) | 2013-03-12 | 2020-04-17 | 分子模板公司 | 用于引起细胞内化的cd20结合免疫毒素及其使用方法 |
| EP2978444B1 (en) | 2013-03-28 | 2018-12-05 | Invectys | A cancer vaccine for dogs |
| DK2978445T3 (en) | 2013-03-28 | 2018-10-15 | Invectys | A CANCERVACCINE FOR CAT |
| BR112016008807B1 (pt) | 2013-10-28 | 2021-07-06 | Invectys | uso de um ácido nucleico |
| EP3666290A1 (en) | 2013-10-28 | 2020-06-17 | Invectys | A telomerase encoding dna vaccine |
| KR102500408B1 (ko) | 2014-01-27 | 2023-02-16 | 몰레큘러 템플레이츠, 인코퍼레이션. | 포유류에 적용하기 위한 탈면역된 시가 독소 a 서브유닛 작동체 폴리펩티드 |
| US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| US20170002046A1 (en) * | 2014-03-11 | 2017-01-05 | Molecular Templates, Inc. | Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs |
| DK3139965T3 (da) | 2014-05-07 | 2021-11-22 | Applied Molecular Transport Inc | Fusionsmolekyler afledt af cholix-toksin til oral indgivelse af biologisk aktive stoffer |
| CN113831416A (zh) | 2014-06-11 | 2021-12-24 | 分子模板公司 | 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子 |
| ES2856457T3 (es) | 2015-02-05 | 2021-09-27 | Molecular Templates Inc | Moléculas de unión a CD20 multivalentes que comprenden regiones efectoras de una subunidad de toxina shiga y composiciones enriquecidas de estas |
| CN107849096B (zh) | 2015-05-30 | 2022-05-24 | 分子模板公司 | 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子 |
| AU2016297920A1 (en) | 2015-07-26 | 2018-01-18 | Molecular Templates, Inc. | Cell-targeting molecules comprising shiga toxin A subunit effectors and CD8+ T-cell epitopes |
| WO2017059270A1 (en) * | 2015-10-02 | 2017-04-06 | Regents Of The University Of Minnesota | Deimmunized therapeutic compositions and methods |
| MX2018007204A (es) * | 2015-12-16 | 2018-12-11 | Gritstone Oncology Inc | Identificacion, fabricacion y uso de neoantigeno. |
| WO2017195508A1 (ja) * | 2016-05-09 | 2017-11-16 | 信越化学工業株式会社 | 室温硬化性オルガノポリシロキサン組成物及び該組成物の硬化物でコーティングされた基材 |
| CN114773439A (zh) | 2016-12-07 | 2022-07-22 | 分子模板公司 | 用于位点特异性缀合的志贺毒素a亚基效应子多肽、志贺毒素效应子支架和细胞靶向分子 |
| MX2019008840A (es) * | 2017-01-25 | 2019-09-09 | Molecular Templates Inc | Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+. |
| US20220193129A1 (en) * | 2017-04-27 | 2022-06-23 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents and dosages thereof |
| US11351246B2 (en) | 2017-05-09 | 2022-06-07 | Invectys SAS | Recombinant measles vaccine expressing hTERT |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| AU2018348165B2 (en) | 2017-10-10 | 2025-09-04 | Seattle Project Corp. | Neoantigen identification using hotspots |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
| CA3089154A1 (en) * | 2018-01-26 | 2019-08-01 | Cambridge Enterprise Limited | Peptide exchange protein |
| EP4082558B1 (en) | 2018-03-08 | 2023-08-23 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
| AU2019257343A1 (en) * | 2018-04-17 | 2020-09-10 | Molecular Templates, Inc. | HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds |
| WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
| CN109504683A (zh) * | 2018-11-13 | 2019-03-22 | 广西壮族自治区水产科学研究院 | 罗非鱼的半乳糖凝集素-3基因序列及其克隆方法 |
| CA3127660A1 (en) | 2019-01-23 | 2020-07-30 | Millennium Pharmaceuticals, Inc. | Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors |
| WO2020154475A1 (en) | 2019-01-23 | 2020-07-30 | Molecular Templates, Inc. | Proteins comprising modified immunoglobulin variable light chains |
| EP3914358A1 (en) | 2019-01-23 | 2021-12-01 | Millennium Pharmaceuticals, Inc. | Anti-cd38 antibodies |
| CN116063505B (zh) | 2019-01-30 | 2024-05-03 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| US20220273781A1 (en) * | 2019-07-23 | 2022-09-01 | Deutsches Krebsforschungszentrum | Polypeptides for treatment of aml |
| GB201910605D0 (en) * | 2019-07-24 | 2019-09-04 | Immetacyte Ltd | Tumour infltracting lymphocyte therapy amd uses thereo |
| BR112022002962A2 (pt) | 2019-08-16 | 2022-07-05 | Applied Molecular Transport Inc | Composições, formulações e produção e purificação de interleucina |
| CN114423793A (zh) | 2019-09-18 | 2022-04-29 | 分子模板公司 | 包含志贺菌毒素a亚基支架的pd-l1结合分子 |
| US11918649B2 (en) | 2019-09-18 | 2024-03-05 | Molecular Templates, Inc. | PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds |
| US20210155671A1 (en) | 2019-11-24 | 2021-05-27 | Molecular Templates, Inc. | Uses of cd20-binding molecules and additional therapeutic agents |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| CN113621030B (zh) * | 2020-07-14 | 2023-05-26 | 上海科技大学 | 一种诱导蛋白质降解的多肽及其应用 |
| EP4262858A1 (en) | 2020-12-16 | 2023-10-25 | Molecular Templates, Inc. | Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector |
| WO2022197945A1 (en) | 2021-03-17 | 2022-09-22 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
| US20230357406A1 (en) * | 2022-03-08 | 2023-11-09 | Molecular Templates, Inc. | Ctla-4 binding molecules comprising shiga toxin a subunit scaffolds and uses thereof |
| KR20250164841A (ko) * | 2023-03-31 | 2025-11-25 | 강마-헬스코드 (상하이) 바이오테크 컴퍼니 리미티드 | 융합 단백질 및 대응되는 핵산, 시험관 내 합성 계 및 제조 방법 |
| CN116554300B (zh) * | 2023-04-27 | 2023-10-24 | 湖北医药学院 | 一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用 |
Family Cites Families (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5080898A (en) | 1982-05-12 | 1992-01-14 | The University Hospital | Enzymatically active toxin coupled to a cell-specific ligand |
| US4894443A (en) | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
| US6022950A (en) | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5135736A (en) | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| WO1991009871A1 (en) | 1989-12-22 | 1991-07-11 | Seragen Incorporated | Hybrid molecules having translocation region and cell-binding region |
| US5635384A (en) | 1990-06-11 | 1997-06-03 | Dowelanco | Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using |
| US6146850A (en) | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
| US5621083A (en) | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| US5552144A (en) | 1992-01-22 | 1996-09-03 | Microcarb, Inc. | Immunogenic shiga-like toxin II variant mutants |
| CA2162689C (en) | 1993-05-12 | 2000-07-18 | Marc D. Better | Immunotoxins comprising gelonin and an antibody |
| US5612474A (en) | 1994-06-30 | 1997-03-18 | Eli Lilly And Company | Acid labile immunoconjugate intermediates |
| AU3374795A (en) | 1994-08-29 | 1996-03-22 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
| JPH11506424A (ja) * | 1995-03-24 | 1999-06-08 | オフィディアン ファーマシューティカルズ インコーポレーテッド | ベロ毒素産生大腸菌に対する治療 |
| US5667786A (en) * | 1995-06-07 | 1997-09-16 | Novavax, Inc. | Method for treating tumors with a toxin |
| US5858682A (en) | 1996-08-02 | 1999-01-12 | Pharmingen | E2A/pbx1 fusion protein specific monoclonal antibodies |
| IL128829A (en) | 1996-09-09 | 2005-08-31 | Zealand Pharma As | Solid phase sythesis of peptides with pre-sequences |
| EP0929679A2 (en) | 1996-09-10 | 1999-07-21 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| FR2766193B1 (fr) | 1997-07-18 | 2001-09-14 | Inst Curie | Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique |
| CA2222993A1 (en) | 1998-02-04 | 1999-08-04 | The Ontario Cancer Institute | A method for using a ribosome-inactivating protein complex as a structural template and a molecular search engine in the design, construction and screening of combinatorial protein libraries |
| WO1999062526A2 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| DE69934337T2 (de) | 1998-07-22 | 2007-05-24 | Osprey Pharmaceuticals Ltd., Calgary | Konjugate zur Behandlung von Entzündungskrankheiten und von assozierter Gewebeschädigung |
| AU2004202331A1 (en) | 1998-07-22 | 2004-06-24 | Osprey Pharmaceuticals Limited | Methods and Compositions for Treating Secondary Tissue Damage and Other Inflammatory Conditions and Disorders |
| US6770456B1 (en) | 1998-07-29 | 2004-08-03 | Ludwig Institute For Cancer Research | Endogenous retrovirus tumor associated nucleic acids and antigens |
| DE60040136D1 (de) | 1999-03-16 | 2008-10-16 | Us Gov Nat Inst Health | Ein neues chimäres protein für die prävention und die behandlung einer hiv infektion |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US7144991B2 (en) | 1999-06-07 | 2006-12-05 | Aletheon Pharmaceuticals, Inc. | Streptavidin expressed gene fusions and methods of use thereof |
| US6492498B1 (en) | 1999-11-15 | 2002-12-10 | Regents Of The University Of Minnesota | Multimeric immunotoxins |
| US20010031485A1 (en) * | 2000-03-22 | 2001-10-18 | Sibtech, Inc. | Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments |
| US7267973B2 (en) | 2000-03-22 | 2007-09-11 | Sibtech, Inc. | Nucleic acids encoding recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor |
| SI2857516T1 (sl) | 2000-04-11 | 2017-09-29 | Genentech, Inc. | Multivalentna protitelesa in njihove uporabe |
| US20020127247A1 (en) | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| JP4214397B2 (ja) | 2002-02-04 | 2009-01-28 | 秀男 吉田 | 変異ベロ毒素を用いた抗癌剤 |
| AU2003213580A1 (en) | 2002-02-26 | 2003-09-09 | Genencor International, Inc. | Subtilisin carlsberg proteins with reduced immunogenicity |
| EP1483294B2 (en) | 2002-03-01 | 2019-10-30 | Immunomedics, Inc. | Internalizing anti-cd74 antibodies and methods of use |
| EP1386927B1 (en) | 2002-08-02 | 2005-03-30 | Institut Curie | Shiga toxin B-subunit as a vector for tumor diagnosis and drug delivery to GB3 expressing tumors |
| DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
| AU2003303374A1 (en) | 2002-12-20 | 2004-07-22 | The Johns Hopkins University | Treatment of metastatic cancer with the b-subunit of shiga toxin |
| US7834258B2 (en) | 2003-06-30 | 2010-11-16 | Mu-Hyeon Choe | Dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same |
| US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| ATE468356T1 (de) | 2003-11-25 | 2010-06-15 | Us Gov Health & Human Serv | Mutierte anti-cd22-antikörper und immunkonjugate |
| EP2457577A1 (en) | 2003-11-25 | 2012-05-30 | Anjin Corporation | Diphtheria toxin variant |
| US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
| DE602004027168D1 (de) | 2004-03-26 | 2010-06-24 | Molecular Templates Inc | Bibliothek von toxin mutanten und deren verwendung |
| US8858930B2 (en) * | 2004-10-26 | 2014-10-14 | Chengru Zhu | Live attenuated bacterial vaccine to reduce or inhibit carriage and shedding of enterohemorrhagic Escherichia coli in cattle |
| MX2007011064A (es) | 2005-03-23 | 2008-02-19 | Genmab As | Anticuerpos contra cd38 para tratamiento de mieloma multiple. |
| RS54271B1 (sr) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1) |
| FI20055417A0 (fi) | 2005-07-20 | 2005-07-20 | Glykos Finland Oy | Syöpäpesifiset glykaanit ja niiden käyttö |
| AU2006272597A1 (en) | 2005-07-25 | 2007-02-01 | Emergent Product Development Seattle Llc | Single dose use of CD20-specific binding molecules |
| EP1928907A4 (en) | 2005-08-15 | 2009-03-11 | Univ California | VEGF-ACTIVATED FAS LIGANDS |
| EP1945660B1 (en) | 2005-09-26 | 2014-05-07 | Molecular Templates, Inc. | Library from toxin mutants, and methods of using same |
| GB0524788D0 (en) | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
| CA2633138A1 (en) | 2005-12-23 | 2007-06-28 | Viventia Biotech Inc. | Methods for generating and screening fusion protein libraries and uses thereof |
| ES2532985T3 (es) | 2006-02-16 | 2015-04-06 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Proteínas quiméricas de toxoide de Shiga |
| US7373982B2 (en) | 2006-03-21 | 2008-05-20 | Halliburton Energy Services, Inc. | Cements for use across formations containing gas hydrates |
| WO2008073160A2 (en) | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
| AU2007339753A1 (en) | 2006-12-29 | 2008-07-10 | Osprey Pharmaceuticals Usa, Inc. | Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof |
| CN101622352A (zh) * | 2006-12-29 | 2010-01-06 | 美国奥斯普瑞医药公司 | 选择和产生修饰的毒素、含有修饰的毒素的缀合物的方法及其应用 |
| WO2008097817A2 (en) | 2007-02-02 | 2008-08-14 | Baylor Research Institute | Multivariable antigens complexed with targeting humanized monoclonal antibody |
| GB2456904B8 (en) * | 2007-03-22 | 2009-12-09 | Heptares Therapeutics Ltd | Stable neurotensin receptor mutants |
| CA2691539C (en) | 2007-06-21 | 2014-08-26 | Angelica Therapeutics, Inc. | Modified toxins |
| US7887801B2 (en) | 2007-07-13 | 2011-02-15 | Topotarget Germany Ag | Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins |
| EP2187971A2 (en) | 2007-08-01 | 2010-05-26 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | A fold-back diabody diphtheria toxin immunotoxin and methods of use |
| EP2197903B9 (en) | 2007-09-04 | 2015-04-22 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity |
| US20100298238A1 (en) | 2007-10-08 | 2010-11-25 | Rutgers, The State University | Nontoxic shiga-like toxin mutant compositions and methods |
| EP2048896B1 (en) | 2007-10-12 | 2011-12-21 | STMicroelectronics Srl | Method and circuit for testing an audio high-frequency loudspeaker being part of a loudspeaker system |
| DK2215247T3 (en) | 2007-11-13 | 2014-12-08 | Scripps Research Inst | Preparation of a fusion of cytotoxic antibody toxin into eukaryotic algae |
| EP2215125A1 (en) | 2007-11-27 | 2010-08-11 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| JP5337815B2 (ja) | 2007-12-17 | 2013-11-06 | アンワイヤード プラネット エルエルシー | 多アンテナ受信機干渉除去方法及び装置 |
| US8470314B2 (en) | 2008-02-29 | 2013-06-25 | Angelica Therapeutics, Inc. | Modified toxins |
| CN101629158A (zh) * | 2008-07-17 | 2010-01-20 | 冯书章 | 出血性大肠杆菌o157重组疫苗 |
| MX2011000891A (es) | 2008-07-21 | 2011-06-01 | Immunomedics Inc | Variantes estructurales de anticuerpos para caracteristicas terapeuticas mejoradas. |
| AU2009293640A1 (en) | 2008-09-22 | 2010-03-25 | Calmune Corporation | Methods and vectors for display of 2G12 -derived domain exchanged antibodies |
| CN102257000B (zh) * | 2008-10-21 | 2014-10-08 | 国际疫苗研究所 | 新型志贺氏菌蛋白抗原及方法 |
| CA2748873C (en) * | 2009-01-23 | 2017-09-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods and compositions based on shiga toxin type 2 protein |
| EP2421892A1 (en) | 2009-04-20 | 2012-02-29 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
| EP2456470A1 (en) | 2009-07-22 | 2012-05-30 | Cenix Bioscience GmbH | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
| US9174169B2 (en) | 2009-08-14 | 2015-11-03 | Unifrax I Llc | Mounting mat for exhaust gas treatment device |
| EP2371864A1 (en) | 2010-03-23 | 2011-10-05 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| NZ604003A (en) | 2010-05-27 | 2015-04-24 | Genmab As | Monoclonal antibodies against her2 |
| GB201013989D0 (en) | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| US9321847B2 (en) | 2010-09-20 | 2016-04-26 | Ramot At Tel Aviv University Ltd. | Activatable toxin complexes comprising a cleavable inhibitory peptide |
| PL219845B1 (pl) | 2011-01-05 | 2015-07-31 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| EP2476441A1 (en) * | 2011-01-13 | 2012-07-18 | Universitat Autònoma De Barcelona | Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells |
| JP2014505064A (ja) | 2011-01-26 | 2014-02-27 | セニックス バイオサイエンス ゲーエムベーハー | 自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート |
| CN103458930B (zh) | 2011-02-01 | 2019-10-15 | 健玛保 | 针对cd74的人抗体和抗体-药物缀合物 |
| US20140088019A1 (en) | 2011-02-11 | 2014-03-27 | Zyngenia, Inc. | Monovalent and Multivalent Multispecific Complexes and Uses Thereof |
| US8895006B2 (en) * | 2011-03-04 | 2014-11-25 | Rutgers, The State University Of New Jersey | Ricin ribosome binding protein compositions and methods of use thereof |
| WO2012154530A1 (en) | 2011-05-06 | 2012-11-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Recombinant immunotoxin targeting mesothelin |
| WO2012162418A1 (en) | 2011-05-23 | 2012-11-29 | The University Of North Carolina At Chapel Hill | Methods and compositions for heterodimeric targeting ligands |
| PL397167A1 (pl) | 2011-11-28 | 2013-06-10 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
| EP2817341A4 (en) | 2012-02-23 | 2015-12-02 | Harvard College | MICROBIAL MODIFIED TOXIN RECEPTOR FOR THE DISTRIBUTION OF AGENTS IN CELLS |
| JP2014021782A (ja) | 2012-07-19 | 2014-02-03 | Canon Inc | 画像処理装置、その制御方法及びプログラム |
| EP2740493A1 (en) | 2012-12-05 | 2014-06-11 | Institut Curie | Conjugates of the B-subunit of Shiga toxin for anticancer therapies |
| CN105051067B (zh) | 2013-03-12 | 2020-04-17 | 分子模板公司 | 用于引起细胞内化的cd20结合免疫毒素及其使用方法 |
| EP2778173A1 (en) | 2013-03-15 | 2014-09-17 | Laboratoire Français du Fractionnement et des Biotechnologies | Antibody directed against anthrax toxins and its uses |
| GB2519786A (en) | 2013-10-30 | 2015-05-06 | Sergej Michailovic Kiprijanov | Multivalent antigen-binding protein molecules |
| KR102500408B1 (ko) * | 2014-01-27 | 2023-02-16 | 몰레큘러 템플레이츠, 인코퍼레이션. | 포유류에 적용하기 위한 탈면역된 시가 독소 a 서브유닛 작동체 폴리펩티드 |
| US20160177284A1 (en) | 2014-01-27 | 2016-06-23 | Molecular Templates, Inc. | Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions |
| US20220401568A1 (en) | 2014-01-27 | 2022-12-22 | Molecular Templates, Inc. | Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes |
| US20210138076A2 (en) | 2014-01-27 | 2021-05-13 | Molecular Templates, Inc. | Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes |
| JP6814634B2 (ja) | 2014-02-05 | 2021-01-20 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | リボ毒性の一時的な減少に基づき、細胞毒性組換えポリペプチドをスクリーニングし、選択し、同定する方法 |
| US20170002046A1 (en) | 2014-03-11 | 2017-01-05 | Molecular Templates, Inc. | Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs |
| US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| PL3604333T3 (pl) | 2014-03-11 | 2021-11-08 | Molecular Templates, Inc. | Białka zawierające regiony efektorowe podjednostki a toksyny shiga proksymalnie do końca aminowego oraz celujące w komórki regiony wiążące typu immunoglobuliny zdolne do swoistego wiązania cd38 |
| ES2850999T3 (es) | 2014-03-14 | 2021-09-02 | Raqualia Pharma Inc | Derivados de azaespiro como antagonistas de TRPM8 |
| CN113831416A (zh) | 2014-06-11 | 2021-12-24 | 分子模板公司 | 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子 |
| CA2951887A1 (en) | 2014-06-12 | 2015-12-17 | Cspc Dophen Corporation | Homogenous antibody drug conjugates via enzymatic methods |
| CA2951355C (en) | 2014-06-18 | 2023-10-31 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Car-expressing nk-92 cells as cell therapeutic agents |
| CN105713087B (zh) | 2014-11-12 | 2020-05-08 | 北京康乐卫士生物技术股份有限公司 | 人乳头瘤病毒58型单克隆抗体及其应用 |
| ES2856457T3 (es) | 2015-02-05 | 2021-09-27 | Molecular Templates Inc | Moléculas de unión a CD20 multivalentes que comprenden regiones efectoras de una subunidad de toxina shiga y composiciones enriquecidas de estas |
| SI3265575T1 (sl) | 2015-03-04 | 2021-08-31 | Igm Biosciences, Inc. | Vezne molekule CD20 in njihove uporabe |
| CN107849096B (zh) * | 2015-05-30 | 2022-05-24 | 分子模板公司 | 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子 |
| AU2016297920A1 (en) | 2015-07-26 | 2018-01-18 | Molecular Templates, Inc. | Cell-targeting molecules comprising shiga toxin A subunit effectors and CD8+ T-cell epitopes |
| JP7241541B2 (ja) | 2016-03-29 | 2023-03-17 | エスティーキューブ，インコーポレイテッド | グリコシル化ｐｄ－ｌ１に特異的な二重機能抗体およびその使用方法 |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| JP7011657B2 (ja) | 2016-10-30 | 2022-02-10 | シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド | 抗ｐｄ－ｌ１抗体および変異型 |
| CN114773439A (zh) * | 2016-12-07 | 2022-07-22 | 分子模板公司 | 用于位点特异性缀合的志贺毒素a亚基效应子多肽、志贺毒素效应子支架和细胞靶向分子 |
| WO2018124642A2 (ko) | 2016-12-26 | 2018-07-05 | 단국대학교 천안캠퍼스 산학협력단 | 치수줄기세포의 상아 모전구세포로의 분화용 조성물 및 상아모전구세포 표면에 특이적으로 결합하는 IgG 또는 IgM 타입 단일 클론 항체 |
| MX2019008840A (es) | 2017-01-25 | 2019-09-09 | Molecular Templates Inc | Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+. |
| US20200190138A1 (en) | 2017-02-28 | 2020-06-18 | Chugai Seiyaku Kabushiki Kaisha | Protein purification with protein l |
| PT3592769T (pt) | 2017-03-09 | 2024-07-31 | Genmab As | Anticorpos contra pd-l1 |
| TW201928059A (zh) | 2017-09-25 | 2019-07-16 | 日商Ｊｓｒ股份有限公司 | 免疫球蛋白結合蛋白質，及使用其之親和性載體 |
| AU2019257343A1 (en) | 2018-04-17 | 2020-09-10 | Molecular Templates, Inc. | HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds |
| WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
| CA3127660A1 (en) * | 2019-01-23 | 2020-07-30 | Millennium Pharmaceuticals, Inc. | Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors |
| WO2020154475A1 (en) | 2019-01-23 | 2020-07-30 | Molecular Templates, Inc. | Proteins comprising modified immunoglobulin variable light chains |
| CN114423793A (zh) | 2019-09-18 | 2022-04-29 | 分子模板公司 | 包含志贺菌毒素a亚基支架的pd-l1结合分子 |
| WO2022197945A1 (en) | 2021-03-17 | 2022-09-22 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
-
2015
- 2015-01-26 KR KR1020227001129A patent/KR102500408B1/ko active Active
- 2015-01-26 EP EP15704153.4A patent/EP3099705B1/en active Active
- 2015-01-26 ES ES15704153T patent/ES2749862T3/es active Active
- 2015-01-26 KR KR1020237005041A patent/KR102692200B1/ko active Active
- 2015-01-26 AU AU2015209063A patent/AU2015209063C1/en active Active
- 2015-01-26 AU AU2015209065A patent/AU2015209065C1/en active Active
- 2015-01-26 CN CN202110072027.1A patent/CN112851769A/zh active Pending
- 2015-01-26 EP EP15704427.2A patent/EP3099704B1/en active Active
- 2015-01-26 CN CN202010812476.0A patent/CN111909278B/zh active Active
- 2015-01-26 US US15/114,474 patent/US20160347798A1/en not_active Abandoned
- 2015-01-26 IL IL302552A patent/IL302552B2/en unknown
- 2015-01-26 EP EP21155849.9A patent/EP3868776A1/en active Pending
- 2015-01-26 WO PCT/US2015/012970 patent/WO2015113007A1/en not_active Ceased
- 2015-01-26 EP EP19173105.8A patent/EP3575312A1/en active Pending
- 2015-01-26 JP JP2016546476A patent/JP6655017B2/ja active Active
- 2015-01-26 MX MX2016009807A patent/MX382229B/es unknown
- 2015-01-26 CN CN201580015672.2A patent/CN106414483A/zh active Pending
- 2015-01-26 CN CN201580013355.7A patent/CN106103489B/zh active Active
- 2015-01-26 KR KR1020167022292A patent/KR20160111951A/ko not_active Ceased
- 2015-01-26 IL IL287490A patent/IL287490B/en unknown
- 2015-01-26 WO PCT/US2015/012968 patent/WO2015113005A1/en not_active Ceased
- 2015-01-26 MX MX2016009809A patent/MX394993B/es unknown
- 2015-01-26 ES ES15704427T patent/ES2877356T3/es active Active
- 2015-01-26 US US15/114,487 patent/US20160340394A1/en not_active Abandoned
- 2015-01-26 KR KR1020167022316A patent/KR20160113158A/ko not_active Ceased
- 2015-01-26 IL IL285403A patent/IL285403B2/en unknown
- 2015-01-26 JP JP2016546493A patent/JP6646584B2/ja active Active
- 2015-01-26 KR KR1020237010012A patent/KR102692208B1/ko active Active
- 2015-01-26 CA CA2937407A patent/CA2937407A1/en active Pending
- 2015-01-26 KR KR1020227001124A patent/KR102514910B1/ko active Active
- 2015-01-26 IL IL294746A patent/IL294746B2/en unknown
-
2016
- 2016-07-06 IL IL246632A patent/IL246632B/en active IP Right Grant
- 2016-07-11 IL IL246701A patent/IL246701B/en active IP Right Grant
- 2016-07-27 MX MX2022010376A patent/MX2022010376A/es unknown
- 2016-07-27 MX MX2021005131A patent/MX2021005131A/es unknown
-
2018
- 2018-12-14 US US16/220,468 patent/US20190153044A1/en not_active Abandoned
-
2019
- 2019-06-21 AU AU2019204364A patent/AU2019204364C1/en active Active
- 2019-08-02 AU AU2019210656A patent/AU2019210656C1/en active Active
-
2020
- 2020-01-10 JP JP2020002993A patent/JP2020073569A/ja active Pending
- 2020-01-31 JP JP2020014954A patent/JP2020079267A/ja active Pending
- 2020-03-03 IL IL273035A patent/IL273035B/en unknown
- 2020-11-09 IL IL278586A patent/IL278586B/en unknown
- 2020-12-22 AU AU2020294212A patent/AU2020294212B2/en active Active
-
2021
- 2021-01-21 AU AU2021200390A patent/AU2021200390C1/en active Active
- 2021-04-15 US US17/231,526 patent/US11312751B2/en active Active
- 2021-06-01 JP JP2021092504A patent/JP7229570B2/ja active Active
- 2021-06-11 US US17/345,576 patent/US12065469B2/en active Active
- 2021-06-21 JP JP2021102325A patent/JP7126729B2/ja active Active
-
2022
- 2022-03-28 US US17/705,619 patent/US12037367B2/en active Active
- 2022-08-09 JP JP2022127059A patent/JP7402556B2/ja active Active
- 2022-10-17 AU AU2022256081A patent/AU2022256081B2/en active Active
- 2022-12-15 AU AU2022287636A patent/AU2022287636B2/en active Active
-
2023
- 2023-02-07 JP JP2023016832A patent/JP7442879B2/ja active Active
-
2024
- 2024-05-30 US US18/678,030 patent/US20240409589A1/en active Pending
- 2024-07-10 US US18/768,336 patent/US20240360184A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022166140A5 (enExample) | ||
| JP2022058385A5 (enExample) | ||
| KR101522954B1 (ko) | 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도 | |
| CN109485734B (zh) | 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用 | |
| JP2020513779A5 (enExample) | ||
| US8591893B2 (en) | Paratope and epitope of anti-mortalin antibody | |
| CN117820479A (zh) | 抗il-17a的新型纳米抗体 | |
| JP2006521088A (ja) | 抗活性化ｒａｓ抗体 | |
| CN117820478B (zh) | 纳米抗体的串联分子及其在疾病治疗中的用途 | |
| CN117843803B (zh) | 串联单域抗体及其在疾病治疗中的应用 | |
| KR101963230B1 (ko) | 복수개의 단일 항체를 포함하는 단백질 복합체 | |
| CA3217487A1 (en) | Heterodimeric antibodies and antigen-binding fragment thereof | |
| CN108290942B (zh) | 与人及小鼠信号素3a交联的抗体及其用途 | |
| JPWO2022224997A5 (enExample) | ||
| CN116262786A (zh) | 针对folr1的单域抗体及其衍生蛋白和应用 | |
| CN114478777A (zh) | 针对gpa33的单域抗体及其衍生蛋白和应用 | |
| CN117866903B (zh) | 单域抗体修饰的干细胞及其在疾病治疗中用途 | |
| CN117843777A (zh) | 用于炎性疾病治疗的新型纳米抗体及其产品和方法 | |
| JP6886474B2 (ja) | ヒト及びマウスＳｅｍａ３Ａに交差結合する抗体及びその用途 | |
| WO2023078446A1 (en) | Multispecific antibodies and uses thereof | |
| CN115724988B (zh) | 一种接近天然分子的多肽融合分子 | |
| JP2017014112A (ja) | 抗サバイビン抗体又は抗体誘導体及びそれらの利用 | |
| JPWO2022129560A5 (enExample) | ||
| CN117242086A (zh) | 新型蛋白质 | |
| CN111479827B (zh) | 结合hERG1和hERG1/整联蛋白β1的单特异性和双特异性抗体 |